Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q1 2025
Ginkgo Bioworks Holdings (DNA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Ginkgo Bioworks Holdings (DNA) reported revenue of $48.3M for the first quarter 2025 (Q1 2025), +27% from a year earlier and +10% from the quarter before. Operating margin was -184.1%, net loss $91.0M (188.2% of revenue).
Ginkgo Bioworks Holdings, Q1 2025: revenue $48.3M (+27% year over year), operating margin -184.1%, net loss $91.0M, operating cash flow −$51.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $48.3M | +10% | +27% |
| Operating profit | −$89.0M | — | — |
| Net earnings | −$91.0M | — | — |
| Operating cash flow | −$51.5M | — | — |
What changed
Revenue was $48.3M in Q1 2025, up 27% year over year and up 10% from the previous quarter.
Operating costs exceeded revenue by $89.0M, an operating margin of -184.1%. Total costs fell 36% while revenue rose 27%. The fastest-growing cost line was Other operating costs (+44%). The quarter ended with a net loss of $91.0M, narrower than the previous quarter's $107.5M loss.
Operating cash flow was −$51.5M. Non-cash charges added back $14.8M of depreciation and amortization and $20.4M of share-based compensation. Working capital and other items added $4.2M. Capital expenditures of $7.6M exceeded it, leaving free cash flow of −$59.1M.
Questions
What was Ginkgo Bioworks Holdings' revenue in the first quarter 2025?
Ginkgo Bioworks Holdings (DNA) reported revenue of $48.3M for the first quarter 2025 (Q1 2025), +27% from a year earlier and +10% from the quarter before.
Was Ginkgo Bioworks Holdings profitable in the first quarter 2025?
Operating loss was $89.0M (-184.1% of revenue) and net loss $91.0M.